COMMUNIQUÉS West-GlobeNewswire

-
EssilorLuxottica: Publication of the 2024 Interim Financial Report
26/07/2024 -
EssilorLuxottica: Mise à disposition du Rapport financier semestriel 2024
26/07/2024 -
eLabNext and ABI-LAB Announce Strategic Partnership to Foster Innovation in Life Sciences
26/07/2024 -
BioPorto to Debut FDA Approved ProNephro AKI at Upcoming ADLM 2024 Clinical Lab Expo
26/07/2024 -
Junshi Biosciences Announces Positive Opinion from the European Medicines Agency’s CHMP For Toripalimab
26/07/2024 -
Psyence Group's NASDAQ-Listed Associate, Psyence Biomedical, Announces Export of Nature-Derived Psilocybin to Australia and Provides Update on Upcoming Phase IIb Trial
26/07/2024 -
Innovation Value Institute Analysis Demonstrates HeartSciences’ MyoVista® wavECG™ Potential to Improve Cardiovascular Pathway Efficiency
26/07/2024 -
Allarity Therapeutics Announces Postponement of Annual Stockholders Meeting
26/07/2024 -
ProMIS Neurosciences Reports Positive Top-Line Data from its Phase 1a Alzheimer's Trial
26/07/2024 -
OneMedNet Announces $4.6 Million Private Placement
26/07/2024 -
ProMIS Neurosciences Announces Up to $122.7 Million Private Placement Financing
26/07/2024 -
Silo Pharma to Present at H.C. Wainwright Annual Global Investment Conference
26/07/2024 -
CHMP recommends RYBREVANT®▼ (amivantamab) in combination with chemotherapy for the treatment of adult patients with advanced EGFR-mutated non-small cell lung cancer (NSCLC) after failure of prior therapy
26/07/2024 -
TRxADE Health, Inc. Announces Business Combination with Scienture, Inc., in a Transaction Valued at $103 Million
26/07/2024 -
Krystal Biotech to Report Second Quarter 2024 Financial Results on August 5, 2024
26/07/2024 -
Predictive Oncology Announces Exercise of Warrants for $1.26 Million Gross Proceeds
26/07/2024 -
Genetic Technologies Strategic Restructure Driving USA Sales Growth
26/07/2024 -
GENFIT: Positive Opinion from EMA Committee for Ipsen’s Iqirvo® (elafibranor) in Primary Biliary Cholangitis
26/07/2024 -
GENFIT : Avis positif du Comité des médicaments à usage humain (CHMP) pour l’Iqirvo® (élafibranor) d’Ipsen dans la Cholangite Biliaire Primitive
26/07/2024
Pages